Publication: Chimeric dengue type 2/type 1 viruses induce immune responses in cynomolgus monkeys
Issued Date
2002-12-01
Resource Type
ISSN
01251562
Other identifier(s)
2-s2.0-0038150175
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Southeast Asian Journal of Tropical Medicine and Public Health. Vol.33, No.3 (2002), 589-599
Suggested Citation
Siritorn Butrapet, Jundee Rabablert, Subhkij Angsubhakorn, Witawat Wiriyarat, Claire Huang, Richard Kinney, Sakol Punyim, Natth Bhamarapravati Chimeric dengue type 2/type 1 viruses induce immune responses in cynomolgus monkeys. Southeast Asian Journal of Tropical Medicine and Public Health. Vol.33, No.3 (2002), 589-599. Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/20295
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Chimeric dengue type 2/type 1 viruses induce immune responses in cynomolgus monkeys
Abstract
Chimeric dengue type 2/type 1 (DEN2/1) viruses, which contain the structural genes of the dengue-1 (16007) parental virus and the nonstructural genes of the DEN2-PDK53 virus, have been constructed. These DEN2/1 viruses induce high levels of DEN1 virus-specific neutralizing antibodies in mice. In this study, the DEN2/1 viruses induced DEN1 virus-specific neutralizing antibodies without the development of viremia in cynomolgus monkeys. Dengue virus-specific IgM antibodies were detected in the sera of the immunized animals as early as 3 days post-immunization. After challenge with the DEN 1-16007 wild-type virus, only a low level of viremia was detected in chimeric DEN2/1 virus-immunized monkeys. A second challenge, with DEN2-16681 virus, was given while the levels of DEN2-specific neutralizing antibodies were very low: infectious Dengue 2 virus could not be detected in sera of the monkeys. A correlation between the level of neutralizing antibody and the incidence of viremia could not be found. In addition, there was no significant increase in the levels of interferon gamma and soluble interleukin 2 receptor in the sera of the challenged monkeys, which suggests a reduction in immunopathogenesis caused by T-cell activation. Our findings suggest that DEN2/1 viruses may used as a liveattenuated candidate vaccine because of their safety, broad immunogenicity, and lower immunopathogenicity.